Delaware biotech iBio pursuing Fabry disease biosimilar ERT
This article was originally published in Scrip
Executive Summary
After acquiring certain rights from Kentucky Bioprocessing for an undisclosed amount, Newark, Delaware-based iBio has started a programme to develop a biosimilar version of an enzyme to treat Fabry disease, a rare, inherited progressive disease caused by a deficiency of the alpha galactosidase A (α-Gal A) enzyme, whose function is to break down a fatty substance known as globotriaosylceramide.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.